Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or quantified.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimal <i>N</i>-methylated and stapled peptide inhibitors of the autophagy protein GABARAP.

RSC chemical biology·2026
Same author

Minimal <i>N</i> -methylated and stapled peptide inhibitors of the autophagy protein GABARAP.

bioRxiv : the preprint server for biology·2026
Same author

DIRAS3-derived cyclic peptides disrupt KRAS-RAF interaction and KRAS nanoclustering, suppressing KRAS-driven pancreatic and ovarian tumors.

iScience·2025
Same author

Accurate de novo design of high-affinity protein-binding macrocycles using deep learning.

Nature chemical biology·2025
Same author

Exploring Arylidene-Indolinone Ligands of Autophagy Proteins LC3B and GABARAP.

ACS medicinal chemistry letters·2025
Same author

Accurate <i>de novo</i> design of high-affinity protein binding macrocycles using deep learning.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: May 7, 2026

The Determination of Protease Specificity in Mouse Tissue Extracts by MALDI-TOF Mass Spectrometry: Manipulating PH to Cause Specificity Changes
09:47

The Determination of Protease Specificity in Mouse Tissue Extracts by MALDI-TOF Mass Spectrometry: Manipulating PH to Cause Specificity Changes

Published on: May 25, 2018

Versatile substrates and probes for IgA1 protease activity.

Santosh K Choudary1, Jiazhou Qiu, Andrew G Plaut

  • 1Department of Chemistry, Tufts University, 62 Talbot Avenue, Medford MA 02155 (USA).

Chembiochem : a European Journal of Chemical Biology
|September 17, 2013
PubMed
Summary

Researchers developed novel peptide substrates and a fluorescence probe to study bacterial immunoglobulin A1 (IgA1) proteases. This tool enables quantification of IgA1 protease activity and the screening for inhibitors, aiding infection research.

Keywords:
bacterial meningitishigh-throughput screeningimmunoglobulinspeptidesproteases

More Related Videos

High-throughput Screening of Carbohydrate-degrading Enzymes Using Novel Insoluble Chromogenic Substrate Assay Kits
06:51

High-throughput Screening of Carbohydrate-degrading Enzymes Using Novel Insoluble Chromogenic Substrate Assay Kits

Published on: September 20, 2016

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
11:01

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase

Published on: November 23, 2016

Related Experiment Videos

Last Updated: May 7, 2026

The Determination of Protease Specificity in Mouse Tissue Extracts by MALDI-TOF Mass Spectrometry: Manipulating PH to Cause Specificity Changes
09:47

The Determination of Protease Specificity in Mouse Tissue Extracts by MALDI-TOF Mass Spectrometry: Manipulating PH to Cause Specificity Changes

Published on: May 25, 2018

High-throughput Screening of Carbohydrate-degrading Enzymes Using Novel Insoluble Chromogenic Substrate Assay Kits
06:51

High-throughput Screening of Carbohydrate-degrading Enzymes Using Novel Insoluble Chromogenic Substrate Assay Kits

Published on: September 20, 2016

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
11:01

Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase

Published on: November 23, 2016

Area of Science:

  • Microbiology
  • Biochemistry
  • Enzymology

Background:

  • Bacterial meningitis is a life-threatening infection.
  • Pathogenic bacteria like Neisseria, Haemophilus, and Streptococcus use immunoglobulin A1 (IgA1) proteases for colonization and immune evasion.
  • Existing knowledge of IgA1 protease substrates is limited.

Purpose of the Study:

  • To design and characterize novel peptide substrates for bacterial IgA1 proteases.
  • To develop a sensitive assay for quantifying IgA1 protease activity.
  • To establish a high-throughput screening method for IgA1 protease inhibitors.

Main Methods:

  • Design and synthesis of diverse peptide substrates based on bacterial IgA1 proteases.
  • Characterization of protease selectivity profiles using these peptide substrates.
  • Development of a fluorescence probe assay for IgA1 protease activity measurement.
  • Application of the probe in buffer and human cerebrospinal fluid.
  • Establishment of a high-throughput screen for IgA1 protease inhibitors.

Main Results:

  • Diverse IgA1 proteases exhibited unexpected selectivity profiles on the designed peptide substrates.
  • A fluorescence probe accurately quantified IgA1 protease activity, detecting Haemophilus influenzae type 1 IgA1 protease at <1 μg/mL.
  • The first high-throughput screen for IgA1 protease inhibitors was successfully established.

Conclusions:

  • Novel peptide substrates and a fluorescence probe provide valuable tools for studying bacterial IgA1 proteases.
  • These tools facilitate the investigation of IgA1 protease roles in bacterial pathogenesis.
  • The developed screening platform enables the discovery of potential therapeutic inhibitors.